CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Forest Laboratories, LLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Forest Laboratories, LLC
909 Third Avenue
Phone: (212) 421-7850p:212 421-7850 NEW YORK, NY  10022  United States Fax: (302) 636-5454f:302 636-5454

This company ceased filing statements with the SEC on 7/15/2014.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Forest Laboratories, LLC (Forest) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company’s products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder. In February 2014, it acquired Aptalis. In February 2014, Mayne Pharma Group Ltd completed the acquisition of the ESGIC, ESGIC PLUS, LORCET and LORCET PLUS brands and related assets from Forest Laboratories, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20143/31/2014YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board HowardSolomon 86 10/1/2013 1/1/1964
President, Chief Executive Officer, Director Brenton L.Saunders 43 10/1/2013 8/18/2011
Chief Financial Officer, Executive Vice President Francis I.Perier 51 12/9/2013 9/27/2004
12 additional Officers and Directors records available in full report.

Business Names
Business Name
3948587 Canada Inc.
AHI C.V.
AHI CV HoldCo, LLC
59 additional Business Names available in full report.

General Information
Number of Employees: 6,200 (As of 3/31/2014)
Outstanding Shares: 272,594,304 (As of 5/29/2014)
Shareholders: 814
Stock Exchange: NYSE
Federal Tax Id: 111798614
Fax Number: (302) 636-5454
Email Address: investor.relations@frx.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023